UTMD — Utah Medical Products Share Price
- $232.06m
- $142.84m
- $50.22m
- 96
- 59
- 39
- 70
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.87 | ||
Price to Tang. Book | 2.18 | ||
Price to Free Cashflow | 12.84 | ||
Price to Sales | 4.98 | ||
EV to EBITDA | 7.37 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 12.08% | ||
Return on Equity | 12.72% | ||
Operating Margin | 32.71% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 46.9 | 42.18 | 49.05 | 52.28 | 50.22 | n/a | n/a | 3.64% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -5.41 | -22.12 | +34.29 | +15.41 | +6.07 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety.
Directors
- Kevin Cornwell CHM (74)
- Brian Koopman CFO
- Ernst Hoyer LED (83)
- Paul Richins DRC (60)
- James Beeson IND (79)
- Barbara Payne IND (74)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 21st, 1978
- Public Since
- December 1st, 1982
- No. of Shareholders
- 2,000
- No. of Employees
- 169
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 3,477,117
- Address
- 7043 S 300 West, MIDVALE, 84047
- Web
- http://www.utahmed.com
- Phone
- +1 8015661200
- Auditors
- Haynie & Co.
Upcoming Events for UTMD
Q4 2024 Utah Medical Products Inc Earnings Release
Similar to UTMD
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 23:55 UTC, shares in Utah Medical Products are trading at $66.74. This share price information is delayed by 15 minutes.
Shares in Utah Medical Products last closed at $66.74 and the price had moved by -24.29% over the past 365 days. In terms of relative price strength the Utah Medical Products share price has underperformed the S&P500 Index by -43.42% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Utah Medical Products dividend yield is 1.8% based on the trailing twelve month period.
Last year, Utah Medical Products paid a total dividend of $1.20, and it currently has a trailing dividend yield of 1.8%.Looking ahead, the next dividend pay date is 2024-10-04.
We do not have data on when Utah Medical Products is to next pay dividends. The historic dividend yield on Utah Medical Products shares is currently 1.8%.
To buy shares in Utah Medical Products you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $66.74, shares in Utah Medical Products had a market capitalisation of $232.06m.
Here are the trading details for Utah Medical Products:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: UTMD
Based on an overall assessment of its quality, value and momentum Utah Medical Products is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Utah Medical Products. Over the past six months, its share price has underperformed the S&P500 Index by -14.23%.
As of the last closing price of $66.74, shares in Utah Medical Products were trading -6.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Utah Medical Products PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $66.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Utah Medical Products' management team is headed by:
- Kevin Cornwell - CHM
- Brian Koopman - CFO
- Ernst Hoyer - LED
- Paul Richins - DRC
- James Beeson - IND
- Barbara Payne - IND